Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Shilpa Medicare's share price for the quarter that ended in Mar. 2026 was ₹348.9. Shilpa Medicare's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 196 Mil. Therefore, Shilpa Medicare's market cap for the quarter that ended in Mar. 2026 was ₹68,239 Mil.
Shilpa Medicare's quarterly market cap
declined
from Sep. 2025 (₹73,656 Mil) to Dec. 2025 (₹62,811 Mil) but then
increased
from Dec. 2025 (₹62,811 Mil) to Mar. 2026 (₹68,239 Mil).
Shilpa Medicare's annual market cap
increased
from Mar. 2024 (₹39,977 Mil) to Mar. 2025 (₹64,875 Mil) and
increased
from Mar. 2025 (₹64,875 Mil) to Mar. 2026 (₹68,239 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shilpa Medicare's Enterprise Value for Today is ₹126,854 Mil.
Shilpa Medicare (NSE:SHILPAMED) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shilpa Medicare Market Cap Related Terms
Shilpa Medicare Market Cap Historical Data
* Premium members only.
The historical data trend for Shilpa Medicare's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Market Cap distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Shilpa Medicare's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare (NSE:SHILPAMED) has a Market Cap of ₹121,173 Mil as of Jul. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shilpa Medicare and its competitors. According to the industry distribution chart, Shilpa Medicare ranks #209 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Shilpa Medicare's Market Cap too high?
Shilpa Medicare's current Market Cap is ₹121,173 Mil. Based on the distribution chart, Shilpa Medicare ranks #209 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #209 out of 1024 companies for Market Cap. This places Shilpa Medicare in the top 20% of its industry — outperforming the majority of peers. The industry median Market Cap is 225.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 225.62, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median Market Cap is 225.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current Market Cap is ₹121,173 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.78, compared to a current price of ₹620.25 — trading 59.9% above its estimated fair value. The current Market Cap is ₹121,173 Mil. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current Market Cap is ₹121,173 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹620.25 is trading 59.9% above its estimated GF Value™ of ₹387.78.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
Market Cap: ₹121,173 Mil
GF Value™: ₹387.78 vs. price of ₹620.25 (59.9% above fair value)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for NSE:SHILPAMED
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
